The most important things about Netflix and Biontech in advance:
- Netflix with successful films and a slowdown in growth
- Biontech is developing two promising corona vaccines
For the second time in a row, Netflix has increased the number of new subscribers by more than 10 million in a quarter. At 15.8 million, however, growth in the first quarter of the year was significantly stronger than in the second. The current results for the second quarter were also mixed: earnings per share of $ 1.59 were below analysts’ expectations (FactSet), while sales of $ 6.15 billion exceeded expectations.
However, the weak outlook for the second half of the year weighed more heavily. The streaming service expects subscriber numbers to slow down for the rest of the year due to the robust first half. Numerous customers would have preferred membership due to the coronavirus pandemic. Netflix gained almost 26 million new customers in the first half of the year, compared to 12 million in the previous year. In addition, the Group expects its productions to take a longer break in the first half of 2021 due to the pandemic. Nevertheless, the group is well positioned: Of the 20 films most viewed in the USA in the second quarter, 7 come from Netflix productions. The stock fell around 8 percent after the exchange.
In the long term, however, the Netflix share rose significantly by more than 60 percent this year. The share of the Mainz biotechnology company Biontech climbed even more strongly by more than 120 percent. The company is researching a vaccine against Covid-19. Two means are relatively far advanced. The US health agency has recognized this and granted accelerated approval to the Mainz company’s vaccine candidates. These are BNT162b1 and BNT162b2.
With the so-called “Fast Track Status”, the FDA wants to facilitate the development of important new drugs and vaccines. This should also speed up their review. In the end, it is a matter of making the medication or vaccines available to the patient more quickly. BNT162b1 and BNT162b2 are Biontech’s most advanced coronavirus vaccine candidates out of a total of four from the company’s project. Biontech researches and develops in this area with the pharmaceutical giant Pfizer at its side. Biontech plans to launch a clinical efficacy study with up to 30,000 participants later this month.
When purchasing certificates and leverage products, investors should familiarize themselves with how it works and be aware of the opportunities and risks. Investors should be aware of the increased risks associated with leverage products. In addition, attention should be paid to the creditworthiness and thus the default risk of the issuer. Further important and worth knowing information about our products can be obtained by calling 0800 4000 910 free of charge or on our website www.hsbc-zertifikate.de.
Click here for the HSBC homepage
This document was created by HSBC Trinkaus & Burkhardt AG (“HSBC”). It is for information purposes only and may not be passed on to third parties without the express written consent of HSBC. The document is a marketing tool. The legal requirements for impartiality of financial analyzes have not been met. There is no prohibition on trading the financial products discussed before the publication of this presentation (“front running”). The document also does not replace specialist investment advice tailored to individual requirements. A drawing offer is also not yet connected to this. The document is only intended for people who have their permanent place of residence in Germany or Austria. It is not intended for recipients in other jurisdictions, and especially not for U.S. citizens. Any information provided on historical performance (including simulations) and forecasts of future performance of the financial products / financial indices shown are not a reliable indicator of future performance. If the financial products discussed are quoted in a currency other than EUR, the return may rise or fall due to currency fluctuations. The tax treatment of an investment depends on the personal circumstances of the investor and may be subject to future changes. The information given in this document is based on sources that we believe to be reliable but have not been subjected to a neutral review. We accept no liability and assume no liability for the correctness and completeness of the information contained herein.
The basic prospectuses as well as the final terms and the basic information sheets are available here. By entering the respective WKN in the search field or via the “Products” tab, you will get to the single product view. There you can find the relevant final terms for the individual products under “Downloads”, which contain the offer terms that apply to the respective security, including the relevant emission terms, as well as the relevant basic information sheets.
BaFin’s approval of the base prospectus should not be understood as its approval of the securities offered. We recommend that prospective and prospective investors read the base prospectus and final terms before making an investment decision in order to obtain as much information as possible, in particular about the potential risks and opportunities of the security.
You are about to purchase a product that is not easy and can be difficult to understand.
“DAX®”, “TecDAX®”, “MDAX®”, “VDAX-NEW®”, “SDAX®”, “DivDAX®”, “ÖkoDAX®”, “Entry Standard Index”, “X-DAX®” and “GEX®” are the intellectual property (including registered trademarks) of Deutsche Börse AG (“DBAG”), Deutsche Börse Group or its licensors and is used under a license. The securities are neither promoted nor advertised, distributed or supported in any other way by DBAG, Deutsche Börse Group or its licensors, research partners or data providers, and DBAG, Deutsche Börse Group and its licensors, research partners or data providers do not accept any liability and close any claims Liability (from negligent as well as from other behavior) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.
EURO STOXX 50®, STOXX 50®, STOXX® 600 and its brands, STOXX® Europe 600 Oil & Gas, STOXX® Europe 600 Basic Resources, EURO STOXX 50® DVP are the intellectual property (including registered trademarks) of STOXX Ltd., Zug, Switzerland (“STOXX”), the Deutsche Börse Group or its licensor and is used under a license. The securities are neither promoted nor advertised, distributed or supported in any other way by STOXX, Deutsche Börse Group or its licensors, research partners or data providers, and STOXX, Deutsche Börse Group and its licensors, research partners or data providers do not accept any liability and exclude any Liability (from negligent as well as from other behavior) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.
The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s®, S & P® and S&P 500® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and further licensed by the licensee for certain purposes. The Licensee’s products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates, and neither party makes any representation regarding the advisability of investing in this product (s) and accepts no liability for errors, omissions or interruptions in the S&P 500 Index.
Nasdaq® and Nasdaq-100 Index® are registered trademarks of Nasdaq, Inc. (together with its affiliates as the “Companies”) and licensed to HSBC Trinkaus & Burkhardt AG for use by them. The companies make no statement about the legality or suitability of the securities. The companies do not issue, recommend, sell or advertise the securities. SOCIETIES DO NOT WARRANT OR TAKE ANY LIABILITY RELATING TO SECURITIES.
The “Dow Jones Industrial Average” is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s® and S & P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and DJIA®, The Dow®, Dow Jones® and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and further licensed by the licensee for certain purposes. The Licensee’s products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates, and neither party makes any representation regarding the advisability of investing in this product (s) and accepts no liability for any errors, omissions, or interruptions in the Dow Jones Industrial Average.
Publisher: HSBC Trinkaus & Burkhardt AG, Königsallee 21/23, 40212 Düsseldorf